Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 73Ovarian Neoplasms 46Lung Neoplasms 26Breast Neoplasms 26Fallopian Tube Neoplasms 23Small Cell Lung Carcinoma 18Carcinoma, Ovarian Epithelial 16Squamous Cell Carcinoma of Head and Neck 14Neoplasms 14Glioblastoma 13Triple Negative Breast Neoplasms 12Recurrence 11Head and Neck Neoplasms 11Lymphoma, Large B-Cell, Diffuse 10Endometrial Neoplasms 10Uterine Cervical Neoplasms 9Colorectal Neoplasms 9Stomach Neoplasms 8Hodgkin Disease 8Brain Neoplasms 8Lymphoma 7Esophageal Neoplasms 7Central Nervous System Neoplasms 7Prostatic Neoplasms 6Neoplasm Metastasis 6Glioma 6Esophageal Squamous Cell Carcinoma 6Astrocytoma 6Adenocarcinoma of Lung 6Mesothelioma 5

Interventions

Fluorouracil 2Cisplatin 2toripalimab 1spartalizumab 1pembrolizumab 1Paclitaxel 1Oxaliplatin 1Irinotecan 1Injections 1Gemcitabine 1Drug Therapy 1Docetaxel 1Carboplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Advanced Malignant Tumors × Carboplatin × Clear all
NCT05229497 2026-03-09

A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors

Akeso

Phase 1/2 Active not recruiting
154 enrolled

Advanced Malignant Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡